Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2015 Feb 11;59(3):1826. doi: 10.1128/AAC.05096-14

Correction for Lanoix et al., Novel Regimens Identified in Mice for Treatment of Latent Tuberculosis Infection in Contacts of Patients with Multidrug-Resistant Tuberculosis

Jean-Philippe Lanoix a, Fabrice Betoudji a, Eric Nuermberger a,b
PMCID: PMC4325801  PMID: 25673825

AUTHOR CORRECTION

Volume 58, no. 4, p. 2316–2321, 2014. Page 2318, Table 2: In the first row under the column heading “Wk 8,” the text should read “rBCG30, 2.62 ± 0.4; H37Rv, 4.78 ± 0.73 (5).”

Page 2318, right column, line 30, to page 3219, left column, line 3: The four complete sentences in this portion of the text should read as follows. “M. tuberculosis CFU counts remained stable or increased slightly in untreated mice thereafter: 4.58 (0.57) at week 4 and 4.78 (0.73) at week 8, similar to those of BALB/c mice. The treatment results of C3HeB/FeJ mice were very similar to those of BALB/c mice, in terms of both the magnitude of the treatment effect and the efficacy rankings. For example, after 2 months of treatment, TMC and RIF were again the most effective monotherapy regimens, followed by INH, Pa, and PNU. As in BALB/c mice, LFX treatment was significantly more active than no treatment in C3HeB/FeJ mice (P = 0.03) but less effective than other drugs.”


Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES